Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference ...

Generic pharmaceuticals contract manufacturing market is booming due to patent expirations, rising demand for biologics, and ...

Teva (TEVA) stock and Alvotech (ALVO) stock in focus as duo launches Selarsdi, a biosimilar to J&J's (JNJ) Stelara after a ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDItm for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination ...

Short interest in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) increased during the last reporting period, rising from 23.22M to 27.13M. This put 2.41% of the company's publicly available shares ...

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States. Selarsdi, like Stelara, is approved for the ...

Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.

The health sector is facing significant changes, with the FDA restricting language, New York suing e-cigarette makers, AstraZeneca expanding in China, Eli Lilly stockpiling weight-loss drugs, Teva and ...

Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...